Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: The LyREMeNET study.
The incidence of neuroendocrine tumors (NETs) is rising, especially in elderly patients. The elderly cancer population present considerable challenges, yet little is known about the characteristics, treatment pattern, and outcomes of metastatic NET patients. The Lyon Real-life Evidence in Metastatic NeuroEndocrine Tumors study (LyREMeNET, NCT03863106) included consecutive metastatic NET patients (mNETs), diagnosed between January 1990 and December 2017. The exclusion criteria were non-metastatic NET, poorly differentiated neuroendocrine carcinoma, and mixed neuroendocrine-nonneuroendocrine neoplasms. We aim to compare patients ≥70 years old (yo) to patients <70 yo. A total of 866 patients were included, 198 (23%) were ≥70 yo. There was no significant difference in characteristics except that elderly patients had more frequently synchronous metastasis. Elderly patients received significantly fewer treatments (median of 2.0 lines vs. 3.0 respectively, p<0.0001), were significantly less frequently treated by chemotherapy (32% vs. 54%), targeted therapy (16% vs. 30%), peptide receptor radionuclide therapy (5% vs. 16%), and they underwent significantly less frequently locoregional intervention. Median overall survival was significantly shorter in elderly patients (5.2 years vs. 9.6 years). The most frequent cause of death was related to disease progression (71%). Multivariate analysis found that, after adjustment for tumor location, tumor grade and number of metastatic sites, age remained significantly associated with overall survival (HR: 1.66, 95%CI [1.26; 2.18]); indicating a poorer survival in patients ≥70 yo in comparison with younger, p=0.0003). Patients ≥70 yo have a worse survival, die frequently from their disease, and are undertreated compared to younger patients.